Laboratory supplies: consolidating the consumables spend, standardising the specification first, treating laboratory consumables as items with a named part number rather than as a category, and keeping a second source for what stops work

The sequence that works

1. Write the specification before chasing price. For each routine item, record what actually matters: material, sterility, certification, dimensions and any compatibility with equipment. Most laboratory arguments about a cheaper supplier are really arguments about an unwritten specification that the new item failed.
2. Consolidate onto fewer suppliers. Fewer suppliers means better pricing, fewer deliveries, fewer invoices and less administration, and it is usually worth more than the last increment of unit price. Consolidation also gives the laboratory leverage it does not have when spend is scattered.
3. Keep a second source for what stops work. For anything whose absence halts work, qualify a second product and keep it qualified. Supply disruption is a routine event rather than an emergency, and the laboratories that cope are the ones that qualified an alternative before they needed it.
4. Hold stock where the lead time is long. Consumables with long or unreliable lead times justify holding stock even at a storage cost. Consumables with short lead times do not, and holding them ties up money and expires on the shelf.
5. Watch the specification creep. Laboratories accumulate premium specifications that nobody chose deliberately: certified nuclease-free tubes for buffer work, the highest purity solvent for a wash step. A periodic review of what is actually required against what is actually ordered usually finds real money.

What not to consolidate

Anything qualified into a validated method stays where it is until a change is assessed and documented, however attractive the alternative price. The cost of requalifying a method exceeds the consumable saving in almost every case.

The same applies to items whose performance is hard to test quickly, such as certified nuclease-free plastics, where a problem is discovered as a failed experiment weeks later rather than at goods-in.

Goods-in, storage and labelling

Check deliveries against the specification rather than the order line, keep certificates where they can be found, and store consumables dry, off the floor and away from anything that punctures packaging. Sterility claims apply only to intact packaging.

Chemical containers must communicate their hazards, and working containers decanted from stock are the ones most often unlabelled. The laboratory's chemical hygiene plan should say plainly how that is handled.

Clinical laboratory supplies, and what the setting adds

Clinical laboratory supplies are the research list with a regulatory layer on top. Tubes, swabs and transport media have to be the right device class for diagnostic use and carry lot traceability; controls and calibrators have to be documented against the assay; and anything touching a patient sample has a disposal route with its own cost. The purchasing consequence is that substitution is not free: swapping a consumable for an equivalent one is a change that a method's validation may not cover, so the supplier's notice period on discontinuation matters more than the unit price.

Lab reagents, and the four questions before any order

A reagent order is four questions. What grade does the method require, since analytical, ACS, HPLC and molecular biology grades differ in the impurities that will show up in your result. What is the pack size against the shelf life, because a litre of something used in millilitres is waste with a hazard label. How does it ship and store, since a cold chain item and a controlled substance each add paperwork. And is it on an approved list, because an accredited method names the grade and sometimes the supplier, and an audit will read the invoice.

Biological reagents, and the storage they demand

Biological reagents are bought against a cold chain and a shelf life rather than a catalogue number. Enzymes and antibodies arrive on ice or dry ice and have to reach their storage temperature the same hour; competent cells and some conjugates do not survive a second freeze-thaw; and anything supplied lyophilised has a different life before and after reconstitution. The purchasing consequences are practical: a named receiving point, aliquoting on arrival so a shared stock is never thawed twice, a temperature log for the freezers, and lot numbers recorded where the result will later be reported.

Medical and lab supplies, and why they are bought differently

The two lists overlap on gloves and tubes and diverge everywhere it matters. A medical supply is a regulated device with a class, a lot number and a traceability obligation, bought against a specification that cannot be substituted freely, and often through a framework or a group contract. A laboratory supply is bought on grade and price, and substitution is a decision the laboratory makes. Mixing the two in one purchasing process is where trouble starts, because a device used on a patient and a consumable used on a bench answer to different rules.

A lab supplies list, and how to build one

A useful list is built from the protocols rather than from a catalogue: walk each method, write down every consumable it touches with the size and the grade, then group by supplier and by storage. Mark the items with a lead time longer than a week and the cold chain items separately, since those are what stop work. Agree one owner for reordering and a minimum stock level per line, and review the list when a method changes rather than when something runs out.

Common questions

How do I reduce laboratory supplies spend?

Write specifications for routine items first, then consolidate onto fewer suppliers, then negotiate. Chasing price before specifying is how laboratories buy cheaper items that do not work.

Should we use a single supplier?

Consolidation is usually worth more than the last increment of unit price, but keep a qualified second source for anything whose absence stops work. Supply disruption is routine rather than exceptional.

Can we switch a consumable used in a validated method?

Not without assessing and documenting the change. Requalifying a method almost always costs more than the consumable saving, so validated items are the wrong place to look for savings.

How much stock should we hold?

Hold stock where lead times are long or unreliable and the item stops work. Do not hold stock of short lead time items, which ties up money and expires on the shelf.

Browse by service class

• Compare Gene synthesis on advertised prices